Celldex Therapeutics

NCT00709462

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

NCT00648102

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

NCT01460134

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

NCT01465139

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

NCT01791686

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

NCT02014909

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

NCT02270372

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

NCT02284971

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

NCT02386111

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

NCT02456701

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

NCT02473731

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

NCT02543645

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

NCT02642016

A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

NCT02837991

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

NCT02924038

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

NCT03329950

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03358719

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT03835533

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT04146129

A Phase 1 Study of CDX-0159

NCT04440943

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

NCT04538794

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04548869

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

NCT05031624

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

NCT04944862

A Study of CDX-0159 in Patients With Prurigo Nodularis

NCT04930783

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

NCT05029999

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

NCT05484011

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05349890

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

NCT05788484

A Study of CDX-585 in Patients With Advanced Malignancies

NCT06650761

A Phase I Study of CDX-622